Objective
EDENT1FI is a unique and timely project building and operationalising an open platform for general population screening of children/adolescents for type 1 diabetes (T1D) throughout Europe. The case is compelling: T1D is a common chronic disease affecting >1 in 300 children or adolescents. Decades of European research have signposted the step-wise nature of T1D development and generated tools for early diagnosis, monitoring and disease modification. EDENT1FI now positions Europe as the leader in early interception of T1D. Our goals are to identify individuals at earlier, pre-clinical stages, dramatically reducing clinical severity at T1D diagnosis and providing the opportunity for interventions with disease modifying therapies to delay or prevent clinical T1D. Spurred by the success of our collaborations in model European childhood screening activities and clinical networks in GPPAD and INNODIA, EDENT1FI will: establish harmonised islet autoantibody surveillance programmes to screen 200,000 children/adolescents across Europe; assess the psychosocial, medical and economic impact of screening in diverse European health systems/populations including underserved families; use state of the art metabolic sensors and biomarkers to optimise monitoring schedules for early-stage (pre-clinical) T1D aligned to maximising compliance and identifying disease progression strata; design SMART trials to expedite evaluation of disease modifying therapies; and inform and educate the public, healthcare professionals, and regulatory authorities of the new paradigms in T1D diagnosis and care. To achieve this, EDENT1FI assembles academic, clinical and industry expertise in screening, clinical care, biomarkers, machine learning, population outreach, ethics, regulatory affairs and policy to accelerate evidence-based early T1D screening into regular healthcare in Europe. The success of these activities will promote early diagnosis and prevention pathways for other chronic childhood diseases.
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
3000 Leuven
Belgium
See on map
Participants (20)
85764 Neuherberg
See on map
8010 Graz
See on map
1060 Saint-Gilles
See on map
150 06 Praha 5
See on map
3400 Hillerod
See on map
20014 Turku
See on map
33100 Tampere
See on map
30173 Hannover
See on map
01069 Dresden
See on map
20132 Milano
See on map
53100 Siena
See on map
02 091 Warszawa
See on map
40 055 Katowice
See on map
1250-203 Lisboa
See on map
65929 Frankfurt Am Main
See on map
4032 SART TILMAN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2880 Bagsvaerd
See on map
6229GW Maastricht
See on map
10004 New York
See on map
10169 New York
See on map
Partners (12)
OX11 0QG Didcot
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
97006 Hillsboro
See on map
1083 HN Amsterdam
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
WC2R 2LS London
See on map
CF24 0DE Cardiff
See on map
OX1 2JD Oxford
See on map
B15 2TT Birmingham
See on map
07701 RED BANK
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
94250 GENTILLY
See on map
08807 Bridgewater
See on map
1131 Tolochenaz
See on map
91325 Northridge
See on map